Personalized Cell Therapy Market to Reach $46.24 Billion by 2029, Expanding at 22.1% CAGR

 Drawing from trusted sources and expert analysis, this report helps businesses navigate the complex landscape of the personalized cell therapy industry.

 

 What Is The Expected CAGR For The Personalized Cell Therapy Market Through 2025?
 The personalized cell therapy market size has grown exponentially in recent years. It will grow from $17.11 billion in 2024 to $20.83 billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to increasing awareness of personalized medicine, increasing healthcare spending, increasing government initiatives, increasing funding for clinical research, rise in neurological disorders.
 
 The personalized cell therapy market size is expected to see exponential growth in the next few years. It will grow to $46.24 billion in 2029 at a compound annual growth rate (CAGR) of 22.1%. The growth in the forecast period can be attributed to rising clinical trials, rising incidence of chronic illnesses, growing geriatric population, rising prevalence of cancer, and increasing adoption of regenerative medicines. Major trends in the forecast period include technological advancements, integration of AI, personalized vaccines, bioinformatics, and microfluidic technologies.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=19137&type=smp
 
 Which Key Factors Will Influence Personalized Cell Therapy Market Growth Over 2025–2034?
 The rise in neurological disorders is expected to drive the growth of the personalized cell therapy market going forward. Neurological disorders are a group of conditions affecting the brain, spinal cord, and nerves, leading to symptoms such as impaired motor function, cognitive deficits, and sensory disturbances. Neurological disorders are occurring due to an aging population, environmental stressors, and lifestyle changes contributing to higher incidences of neurodegenerative diseases. Personalized cell therapy is required for neurological disorders as it offers tailored treatments that target specific patient needs, potentially restoring damaged neural tissue and improving outcomes in complex, individualized conditions. For instance, in December 2022, according to the Parkinson Foundation, a US-based government organization, the yearly incidence of Parkinson’s disease (PD) among older persons is 50% greater than the existing estimate of 60,000 cases. Additionally, 1.2 million more Americans are predicted to have Parkinson’s disease by 2030. Therefore, the rise in neurological disorders is driving the growth of the personalized cell therapy market.
 
 Comprehensive Segment-Wise Insights Into The Personalized Cell Therapy Market
 The personalized cell therapymarket covered in this report is segmented — 
 
 1) By Cell Type: Lymphocytes; Mesenchymal Stem Cell; Hematopoietic Stem Cell; Other Cell Type
 2) By Technique: Platelet Transfusions; Bone Marrow Transplantation; Packed Red Cell Transfusions; Organ Transplantation
 3) By Application: Cardiovascular Diseases; Neurological Disorders; Inflammatory Diseases; Diabetes; Cancer; Other Applications
 4) By End-User: Hospital; Homecare; Specialty Clinics; Other End-User
 
 Subsegments:
 1) By Lymphocytes: T Cells; Natural Killer (NK) Cells; Regulatory T Cells
 2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs; Adipose Tissue-Derived MSCs; Umbilical Cord-Derived MSCs
 3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells; Allogeneic Hematopoietic Stem Cells
 4) By Other Cell Types: Dendritic Cells; Fibroblasts; Endothelial Cells
 
 What Are The Prominent Trends In The Personalized Cell Therapy Market?
 Major companies operating in the personalized cell therapy market are focused on forming strategic partnerships to accelerate the development and commercialization of innovative therapies. These collaborations help companies pool resources, expertise, and technologies to enhance research and development capabilities, streamline clinical trials, and navigate regulatory pathways more efficiently. For instance, in October 2022, Century Therapeutics Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb (BMS), a US-based biopharmaceutical company, to develop and commercialize allogeneic cell therapies. This collaboration uses Century’s innovative induced pluripotent stem cell (iPSC) technology to create engineered natural killer (NK) and T cell therapies to treat hematologic malignancies and solid tumors. The agreement encompasses the development of up to four distinct cell therapy programs, with the initial focus on two specific areas: acute myeloid leukemia (AML) and multiple myeloma. These programs will utilize engineered NK cells or gamma delta T cells derived from iPSCs.
 
 Analysis Of Key Players In Personalized Cell Therapy Market
 Major companies operating in the personalized cell therapy marker are AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Cipla Limited, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd., Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc. 
 
 View the full personalized cell therapy market report here:
 https://www.thebusinessresearchcompany.com/report/personalized-cell-therapy-global-market-report
 
 What Are The Key Regional Trends In The Personalized Cell Therapy Market?
 North America was the largest region in the personalized cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company